Followers | 43 |
Posts | 4254 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Thursday, September 22, 2022 10:03:46 AM
And clear path to Profitability? How? Lol
Negative in every aspect Profitability, Cash Flow Statement, Income Statement & Managment Effectiveness.
Recent SPRO News
- Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 • GlobeNewswire Inc. • 03/06/2024 01:05:00 PM
- Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections • GlobeNewswire Inc. • 02/28/2024 01:05:00 PM
- Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference • GlobeNewswire Inc. • 02/26/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:05:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:53:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:50:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:45:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:44:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:40:36 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:50:10 PM
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/31/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:07:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 01:11:05 PM
- Spero Therapeutics Provides Corporate Update and 2024 Outlook • GlobeNewswire Inc. • 01/05/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:40:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:13:00 PM
- Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections • GlobeNewswire Inc. • 01/02/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:17:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:15:04 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/13/2023 09:50:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/13/2023 09:45:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:13:06 PM
- Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:02:10 PM
- Monday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and more • IH Market News • 11/13/2023 11:45:20 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM